XML 31 R6.htm IDEA: XBRL DOCUMENT v3.25.4
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit 
Beginning balance (in shares) at Dec. 31, 2022   184,135,714      
Beginning balance at Dec. 31, 2022 $ 5,230 $ 2 $ 1,562,247 $ 6 $ (1,557,025)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock, net of issuance costs (in shares)   6,189,974      
Issuance of common stock, net of issuance costs 6,708   6,708    
Proceeds from sale of stock under employee stock purchase plan (in shares)   200,194      
Proceeds from sale of stock under employee stock purchase plan 85   85    
Stock-based compensation expense 9,317   9,317    
Restricted stock unit vesting (in shares)   4,054,407      
Exercise of options (in shares)   2,250      
Exercise of options 1   1    
Net loss (51,925)       (51,925)
Ending balance (in shares) at Dec. 31, 2023   194,582,539      
Ending balance at Dec. 31, 2023 (30,584) $ 2 1,578,358 6 (1,608,950)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock, net of issuance costs (in shares)   27,532,942      
Issuance of common stock, net of issuance costs 42,495   42,495    
Proceeds from sale of stock under employee stock purchase plan (in shares)   189,732      
Proceeds from sale of stock under employee stock purchase plan 153   153    
Stock-based compensation expense 7,775   7,775    
Restricted stock unit vesting (in shares)   2,099,540      
Exercise of options (in shares)   444,239      
Exercise of options 386   386    
Net loss $ (69,410)       (69,410)
Ending balance (in shares) at Dec. 31, 2024 224,848,992 224,848,992      
Ending balance at Dec. 31, 2024 $ (49,185) $ 2 1,629,167 6 (1,678,360)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock, net of issuance costs (in shares)   35,287,364      
Issuance of common stock, net of issuance costs 66,449   66,449    
Warrants exercised, cashless (in shares)   1,408,588      
Warrants exercised, cashless 7,494   7,494    
Proceeds from sale of stock under employee stock purchase plan (in shares)   187,422      
Proceeds from sale of stock under employee stock purchase plan 230   230    
Stock-based compensation expense $ 11,283   11,283    
Restricted stock unit vesting (in shares)   2,486,599      
Exercise of options (in shares) 1,205,853 1,205,853      
Exercise of options $ 1,684   1,684    
Net loss $ (5,345)       (5,345)
Ending balance (in shares) at Dec. 31, 2025 265,424,818 265,424,818      
Ending balance at Dec. 31, 2025 $ 32,610 $ 2 $ 1,716,307 $ 6 $ (1,683,705)